Deficiency of Adenosine Deaminase 2 (DADA2)

  • Andreas Reiff


Deficiency of adenosine deaminase type 2 (DADA2) is a recently discovered, pathogenetically complex autoinflammatory syndrome with features of autoinflammation, immunodeficiency, and autoimmunity. The disease is highly variable in regard to age at onset, disease severity, and organ involvement but typically presents as a childhood-onset vasculopathy resembling polyarteritis nodosa (PAN). Patients with DADA2 characteristically present with livedo racemosa, purpura, leg ulcers, Raynaud’s phenomenon, and digital necrosis and in more severe cases with peripheral neuropathy, and early-onset hemorrhagic and ischemic strokes. Other symptoms include subcutaneous nodules, recurrent fevers, hepatosplenomegaly, ophthalmologic manifestations, hypertension, musculoskeletal symptoms, marrow failure, and hypogammaglobulinemia. Evaluation of ADA2 enzymatic activity and genetic analysis for CECR1 gene mutations may aid in the diagnosis. Treatment for DADA2 is not yet well established and should be based on the individual presentation and severity of the disease.


Deficiency of adenosine deaminase type 2 (DADA2) Autoinflammatory syndrome Polyarteritis Nodosa (PAN) CECR1 gene mutations 


  1. 1.
    Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370:911–20.CrossRefGoogle Scholar
  2. 2.
    Navon Elkan P, Pierce SB, Segel R, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014;370:921–31.CrossRefGoogle Scholar
  3. 3.
    van Montfrans J, Zavialov A, Zhou Q. Mutant ADA2 in vasculopathies. N Engl J Med. 2014;371(5):478.CrossRefGoogle Scholar
  4. 4.
    Bras J, Guerreiro R, Santo GC. Mutant ADA2 in vasculopathies. N Engl J Med. 2014;371(5):478–80.CrossRefGoogle Scholar
  5. 5.
    Van Eyck L, Liston A, Wouters C. Mutant ADA2 in vasculopathies. N Engl J Med. 2014;371(5):480.PubMedGoogle Scholar
  6. 6.
    Garg N, Kasapcopur O, Foster J 2nd, et al. Novel adenosine deaminase 2 mutations in a child with a fatal vasculopathy. Eur J Pediatr. 2014;173(6):827–30.CrossRefGoogle Scholar
  7. 7.
    Adenosine HM, Deficiency D. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. Gene reviews. Seattle: University of Washington; 2006. p. 1993–2018.Google Scholar
  8. 8.
    Zavialov AV, Yu X, Spillmann D, et al. Structural basis for the growth factor activity of human adenosine deaminase ADA2. J Biol Chem. 2010;285:12367–77.CrossRefGoogle Scholar
  9. 9.
    Giannelou A, Zhou Q, Kastner DL. When less is more: primary immunodeficiency with an autoinflammatory kick. Curr Opin Allergy Clin Immunol. 2014;14(6):491–500.CrossRefGoogle Scholar
  10. 10.
    Eltzschig HK, Sitkovsky MV, Robson SC. Purinergic signaling during inflammation. N Engl J Med. 2012;367:2322–33.CrossRefGoogle Scholar
  11. 11.
    Savic S, McDermott MF. Clinical genetics in 2014: new monogenic diseases span the immunological disease continuum. Nat Rev Rheumatol. 2015;11(2):67–8.CrossRefGoogle Scholar
  12. 12.
    Cronstein BN, Eberle MA, Gruber HE, Levin RI. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A. 1991;88(6):2441–5.CrossRefGoogle Scholar
  13. 13.
    Cronstein B. How does methotrexate suppress inflammation? Clin Exp Rheumatol. 2010;28(5 Suppl 61):S21–3. Epub 2010 Oct 28. Review.PubMedGoogle Scholar
  14. 14.
    Zavialov AV, Engstrom A. Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. Biochem J. 2005;391:51–7.CrossRefGoogle Scholar
  15. 15.
    Belot A, Wassmer E, Twilt M, et al. Mutations in CECR1 associated with a neutrophil signature in peripheral blood. Pediatr Rheumatol Online J. 2014;12:44.CrossRefGoogle Scholar
  16. 16.
    McColl SR, St-Onge M, Dussault AA, et al. Immunomodulatory impact of the A2A adenosine receptor on the profile of chemokines produced by neutrophils. FASEB J. 2006;20(1):187–9.CrossRefGoogle Scholar
  17. 17.
    Zavialov AV, Garcia E, Glaichenhaus N, et al. Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J Leukoc Biol. 2010;88:279–90.CrossRefGoogle Scholar
  18. 18.
    Caorsi R, Penco F, Grossi A, Insalaco A, Omenetti A, Alessio M, Conti G, Marchetti F, Picco P, Tommasini A, Martino S, Malattia C, Gallizi R, Podda RA, Salis A, Falcini F, Schena F, Garbarino F, Morreale A, Pardeo M, Ventrici C, Passarelli C, Zhou Q, Severino M, Gandolfo C, Damonte G, Martini A, Ravelli A, Aksentijevich I, Ceccherini I, Gattorno M. Monogenic polyarteritis: the lesson of ADA2 deficiency. Pediatric Rheumatol. 2016;14:51.CrossRefGoogle Scholar
  19. 19.
    Gonzalez Santiago TM, Zavialov A, Saarela J, et al. Dermatologic features of ADA2 deficiency in cutaneous polyarteritis nodosa. JAMA Dermatol. 2015;1. Google Scholar
  20. 20.
    Hashem H, Kelly SJ, Ganson NJ, Hershfield MS. Deficiency of adenosine deaminase 2 (DADA2), an inherited cause of polyarteritis nodosa and a mimic of other systemic rheumatologic disorders. Curr Rheumatol Rep. 2017;19(11):70.CrossRefGoogle Scholar
  21. 21.
    Sahin S, Adrovic A, Barut K, Ugurlu S, Turanli ET, Ozdogan H, Kasapcopur O. Clinical, imaging and genotypical features of three deceased and five surviving cases with ADA2 deficiency. Rheumatol Int. 2018;38(1):129–36.CrossRefGoogle Scholar
  22. 22.
    Ozen S, Pistorio A, Lusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis. 2010;69:798–806.CrossRefGoogle Scholar
  23. 23.
    Gonzalez Santiago TM, Zavialov A, Saarela J, Seppanen M, Reed AM, Abraham RS, Gibson LE. Dermatologic features of ADA2 deficiency in cutaneous polyarteritis nodosa. JAMA Dermatol. 2015;151(11):1230–4.CrossRefGoogle Scholar
  24. 24.
    Van Montfrans JM, Hartman EA, Braun KP, et al. Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. Rheumatology (Oxford). 2016;55(5):902–10.CrossRefGoogle Scholar
  25. 25.
    Batu ED, Karadag O, Taskiran EZ, et al. A case series of adenosine deaminase 2-deficient patients emphasizing treatment and genotype-phenotype correlations. J Rheumatol. 2015;42(8):1532–4.CrossRefGoogle Scholar
  26. 26.
    Wu S, Xu Z, Liang H. Sneddon’s syndrome: a comprehensive review of the literature. Orphanet J Rare Dis. 2014;9:215.CrossRefGoogle Scholar
  27. 27.
    Bolayir E, Yilmaz A, Kugu N, Erdogan H, Akyol M, Akyuz A. Sneddon’s syndrome: clinical and laboratory analysis of 10 cases. Acta Med Okayama. 2004;58(2):59–65. ReviewPubMedGoogle Scholar
  28. 28.
    Nanthapisal S, Murphy C, Omoyinmi E, Hong Y, Standing A, Berg S, Ekelund M, Jolles S, Harper L, Youngstein T, Gilmour K, Klein NJ, Eleftheriou D, Brogan PA. Deficiency of adenosine deaminase type 2: a description of phenotype and genotype in fifteen cases. Arthritis Rheumatol. 2016;68:2314–22.CrossRefGoogle Scholar
  29. 29.
    Brogan P, Eleftheriou D. Vasculitis update: pathogenesis and biomarkers. Pediatr Nephrol. 2018;33(2):187–98. Epub 2017 Aug 7. Review.CrossRefGoogle Scholar
  30. 30.
    Fellmann F, Angelini F, Wassenberg J, et al. IL-17 receptor A and adenosine deaminase 2 deficiency in siblings with recurrent infections and chronic inflammation. J Allergy Clin Immunol. 2016;137(4):1189–96.e2. Epub 2015 Nov 20. CrossRefGoogle Scholar
  31. 31.
    Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1–11.CrossRefGoogle Scholar
  32. 32.
    Schepp J, Bulashevska A, Mannhardt-Laakmann W, et al. Deficiency of adenosine deaminase 2 causes antibody deficiency. J Clin Immunol. 2016;36(3):179–86.CrossRefGoogle Scholar
  33. 33.
    Caorsi R, Penco F, Grossi A, Insalaco A, Omenetti A, Alessio M, Conti G, Marchetti F, Picco P, Tommasini A, Martino S, Malattia C, Gallizi R, Podda RA, Salis A, Falcini F, Schena F, Garbarino F, Morreale A, Pardeo M, Ventrici C, Passarelli C, Zhou Q, Severino M, Gandolfo C, Damonte G, Martini A, Ravelli A, Aksentijevich I, Ceccherini I, Gattorno M. ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Ann Rheum Dis. 2017;76(10):1648–56. Epub 2017 May 18.CrossRefGoogle Scholar
  34. 34.
    Caorsi R, Omenetti A, Picco P, et al. Long-term efficacy of etanercept in ADA2 deficiency. Pediatr Rheumatol Online J. 2014;12(suppl 1):72.CrossRefGoogle Scholar
  35. 35.
    Nihira H, Nakagawa K, Izawa K, Kawai T, Yasumi T, Nishikomori R, Nambu M, Miyagawa-Hayashino A, Nomura T, Kabashima K, Ito M, Iwaki-Egawa S, Sasahara Y, Nakayama M, Heike T. Fever of unknown origin with rashes in early infancy is indicative of adenosine deaminase type deficiency. Scand J Rheumatol. 2017;30:1–3.Google Scholar
  36. 36.
    Van Eyck JL, Hershfield MS, Pombal D, et al. Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency. J Allergy Clin Immunol. 2015;135(1):283–7.CrossRefGoogle Scholar
  37. 37.
    Schepp J, Proietti M, Frede N, Buchta M, Hübscher K, Rojas Restrepo J, Goldacker S, Warnatz K, Pachlopnik Schmid J, Duppenthaler A, Lougaris V, Uriarte I, Kelly S, Hershfield M, Grimbacher B. Screening of 181 patients with antibody deficiency for deficiency of adenosine deaminase 2 sheds new light on the disease in adulthood. Arthritis Rheumatol. 2017;69(8):1689–700. Epub 2017 Jul 5.CrossRefGoogle Scholar
  38. 38.
    Collison J. Autoinflammation: stem cell transplantation for DADA2. Nat Rev Rheumatol. 2017.Google Scholar
  39. 39.
    Hashem H, Kumar AR, Müller I, Babor F, Bredius R, Dalal J, Hsu AP, Holland SM, Hickstein DD, Jolles S, Krance R, Sasa G, Taskinen M, Koskenvuo M, Saarela J, van Montfrans J, Wilson K, Bosch B, Moens L, Hershfield M, Meyts I. Hematopoietic stem cell transplantation rescues the hematological, immunological and vascular phenotype in DADA2. Blood. 2017;130(24):2682–88. Epub 2017 Oct 3.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Andreas Reiff
    • 1
  1. 1.Division Head RheumatologyChildren’s Hospital Los Angeles, USC Keck School of MedicineLos AngelesUSA

Personalised recommendations